Skip to main content
Triangle logo TriangleGet started

Nivolumab (NCT07551583)

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL: a one-minute explainerNCT075515831 min

Nivolumab trial for Hodgkin Lymphoma (NCT07551583). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients aged 2–21 with newly diagnosed, stage I or II classical Hodgkin lymphoma, tumors smaller than ten centimeters, and weight of at least ten kilograms.

The idea: nivolumab releases a PD-1 brake on immune cells. It is combined with doxorubicin, vinblastine, and dacarbazine chemotherapy, all given intravenously twice per 28-day cycle. Response after two cycles guides whether treatment continues to four or six cycles. Researchers assess response and safety.

This phase 2 study plans 15 patients. David McCall leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.